INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of PaciraFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Pacira To Contact Him Directly To Discuss Their Options
Lowey Dannenberg Notifies Pacira Biosciences, Inc. (“Pacira” or the “Company”) (NASDAQ: PCRX) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $100,000 in Losses to Contact the FirmNEW YORK, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, announces the filing of a class action lawsuit against Pacira Biosciences, Inc. (“Pacira” or the “Company”) (
NASDAQPCRX) for violations of the federal securities laws on behalf of investors who purchased or acquired Pacira common stock between August 2, 2023 to August 8, 2024, inclusive (the “Class Period”).
Pacira BioSciences Acquires Remaining Equity Stake of GQ Bio-- Advances Pacira’s “5x30” path to becoming an innovative biopharmaceutical organization --
Pacira BioSciences to Participate in Fireside Chat at Two Healthcare Conferences in MarchPARSIPPANY, N.J., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will participate in an analyst-led fireside chat at the following two healthcare conferences:
Lowey Dannenberg Notifies Pacira Biosciences, Inc. (“Pacira” or the “Company”) (NASDAQ: PCRX) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $100,000 in Losses to Contact the FirmNEW YORK, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, announces the filing of a class action lawsuit against Pacira Biosciences, Inc. (“Pacira” or the “Company”) (
NASDAQPCRX) for violations of the federal securities laws on behalf of investors who purchased or acquired Pacira common stock between August 2, 2023 to August 8, 2024, inclusive (the “Class Period”).
Pacira to Report 2024 Financial Results on Thursday February 27, 2025PARSIPPANY, N.J., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will report its fourth quarter and year ended December 31, 2024 financial results after the close of the U.S. markets on Thursday February 27, 2025. Following the release, the company will host a live conference call and webcast at 4:30 p.m. ET.
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of PaciraFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Pacira To Contact Him Directly To Discuss Their Options
Lowey Dannenberg Notifies Pacira Biosciences, Inc. (“Pacira” or the “Company”) (NASDAQ: PCRX) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $100,000 in Losses to Contact the FirmNEW YORK, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, announces the filing of a class action lawsuit against Pacira Biosciences, Inc. (“Pacira” or the “Company”) (
NASDAQPCRX) for violations of the federal securities laws on behalf of investors who purchased or acquired Pacira common stock between August 2, 2023 to August 8, 2024, inclusive (the “Class Period”).
Lowey Dannenberg Notifies Pacira Biosciences, Inc. (“Pacira” or the “Company”) (NASDAQ: PCRX) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $100,000 in Losses to Contact the FirmNEW YORK, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, announces the filing of a class action lawsuit against Pacira Biosciences, Inc. (“Pacira” or the “Company”) (
NASDAQPCRX) for violations of the federal securities laws on behalf of investors who purchased or acquired Pacira common stock between August 2, 2023 to August 8, 2024, inclusive (the “Class Period”).
Lowey Dannenberg Notifies Pacira Biosciences, Inc. (“Pacira” or the “Company”) (NASDAQ: PCRX) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $100,000 in Losses to Contact the FirmNEW YORK, Feb. 07, 2025 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, announces the filing of a class action lawsuit against Pacira Biosciences, Inc. (“Pacira” or the “Company”) (
NASDAQPCRX) for violations of the federal securities laws on behalf of investors who purchased or acquired Pacira common stock between August 2, 2023 to August 8, 2024, inclusive (the “Class Period”).
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PARSIPPANY, N.J., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced the granting of inducement awards on February 4, 2025 to 15 new employees under Pacira’s Amended and Restated 2014 Inducement Plan (the “Inducement Plan”) as a material inducement to each employee's entry into employment with the company. In accordance with Nasdaq Listing Rule 5635(c)(4), the awards were approved by the Compensation Committee of the Board of Directors (the “Committee”) without stockholder approval.
Lowey Dannenberg Notifies Pacira Biosciences, Inc. (“Pacira” or the “Company”) (NASDAQ: PCRX) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $100,000 in Losses to Contact the FirmNEW YORK, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, announces the filing of a class action lawsuit against Pacira Biosciences, Inc. (“Pacira” or the “Company”) (
NASDAQPCRX) for violations of the federal securities laws on behalf of investors who purchased or acquired Pacira common stock between August 2, 2023 to August 8, 2024, inclusive (the “Class Period”).
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of PaciraFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Pacira To Contact Him Directly To Discuss Their Options
PCRX Stockholders Should Contact Shareholder Rights Firm Robbins for Information About the Class Action Against Pacira BioSciences, Inc.SAN DIEGO, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired Pacira BioSciences, Inc. (
NASDAQPCRX) securities between August 2, 2023 and August 8, 2024. Pacira is an American pharmaceutical company committed to developing and providing non-opioid pan management and regenerative health solutions.
Lowey Dannenberg Notifies Pacira Biosciences, Inc. (“Pacira” or the “Company”) (NASDAQ: PCRX) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $100,000 in Losses to Contact the FirmNEW YORK, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, announces the filing of a class action lawsuit against Pacira Biosciences, Inc. (“Pacira” or the “Company”) (
NASDAQPCRX) for violations of the federal securities laws on behalf of investors who purchased or acquired Pacira common stock between August 2, 2023 to August 8, 2024, inclusive (the “Class Period”).
Pacira Announces Updates to Board of Directors-- Accomplished Business and Financial Leader, Laura Brege, Appointed Chair --
DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of PaciraFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Pacira To Contact Him Directly To Discuss Their Options
